SecBot SecBot
144 ·Filed Jun 23, 2026

NUVB

Nuvation Bio Inc.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001950047-26-006426
Form 144 — notice of proposed sale of securities
Actionable Insight ▼ Bearish

Multiple insider sell signals in a short window (this + $1.4M prior) raise caution. Monitor for additional Form 144 or Form 4 filings. If selling accelerates, it may suggest insider concern ahead of upcoming catalysts or results.

DirectionBearish
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
NUVB ▼ -6.04% at T+60d
SHORT call ✓ call won +6.04% · α vs SPY +8.88% · entry $6.46 → $6.07
Entry = T+0 close
Jun 23, 2026
via day close
T+1d
-10.06%
call +10.06% · α +10.21%
$5.81
settled 4mo ago
T+5d
-16.10%
call +16.10% · α +17.81%
$5.42
settled 4mo ago
T+20d
+1.39%
call -1.39% · α +0.54%
$6.55
settled 3mo ago
T+60d
-6.04%
call +6.04% · α +8.88%
$6.07
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Stacy Markel, an officer of Nuvation Bio, filed a Form 144 on June 23, 2026, indicating intent to sell 125,000 shares of common stock, with an approximate market value of $720,000. This follows a period of insider selling ($1.4M over 30 days) and poor recent stock performance.

Key Facts

  • Insider (Officer) Stacy Markel intends to sell 125,000 shares valued at approximately $720,000.
  • Form 144 filed on June 23, 2026, representing an advance notice of intent to sell restricted securities.
  • Shares acquired via exercise of stock options on the same date (June 23, 2026), paid in cash.
  • Prior 30-day insider activity at Nuvation Bio: 3 sells totaling $1.4 million.

Financial Impact

Insider intends to sell $720k worth of shares; aggregate 30-day insider selling now $2.12M.

dilutioninsider holdings

Risk Factors

  • Insider selling can signal lack of confidence or need for liquidity ahead of negative news.
  • Options exercise and immediate sale dilutes holdings and may pressure stock near-term.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006426
Document: 0001950047-26-006426-index.html0001950047-26-006426
Document: 0001950047-26-006426.txt0001950047-26-006426
8 reports for NUVB
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NUVB — sortable, filterable
TypeNow
Oct 21, 2026
4d ago
Press Release
NEUTRAL ★ 1/10
$4.70awaiting T+60—$4.57 (−2.87%)
Aug 6, 2026
11w ago
8-K
MIXED ★ 5/10
$6.11awaiting T+60—$4.57 (−25.29%)
Jun 26, 2026
17w ago
424B5
BEARISH ★ 6/10
$5.61 $6.10▼ −8.73%▼ −4.35%$4.57 (+18.63%)
Jun 23, 2026
17w ago
144
BEARISH ★ 6/10
$6.46 $6.07▲ +6.04%▲ +8.88%$4.57 (+29.33%)
Jun 23, 2026
17w ago
144
NEUTRAL ★ 3/10
$6.46 $6.07▼ −6.04%▼ −8.88%$4.57 (−29.33%)
May 4, 2026
24w ago
8-K
MIXED ★ 6/10
$4.83 $6.70▲ +38.72%▲ +35.98%$4.57 (−5.49%)
Apr 21, 2026
26w ago
DEFA14A
NEUTRAL ★ 2/10
$5.11 $5.64▲ +10.37%▲ +3.47%$4.57 (−10.67%)
Apr 17, 2026
27w ago
144
NEUTRAL ★ 3/10
$5.12 $5.90▲ +15.23%▲ +8.46%$4.57 (−10.84%)
Showing 8 of 8

US Market Status

Market Open — Closes in 5h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026